Am J Transplant, Volume 21, Suppl 3 Archives - Page 52 of 139 - ATC Abstracts

2021 American Transplant Congress
Changes in Body Mass Index Before and After Kidney Transplant
M. Laub¹, S. Finder², P. Harikrishnan¹, M. Simon³, I. Gani¹, M. Saeed¹, R. Kapoor¹
¹Augusta University Medical Center, Augusta, GA, ²Vanderbilt University Medical Center, Nashville, TN, ³Brandon Wilde, Augusta, GA
*Purpose: Describe changes in body mass index (BMI) before and after kidney transplant and determine the association between BMI and graft loss or mortality.*Methods: Single…
2021 American Transplant Congress
Immunosuppression Regimen and Risk of Posttransplant Diabetes Among Older Kidney Transplant Recipients
K. Lentine¹, J. Ahn², M. McAdams Demarco², H. Xiao¹, S. Bunnapradist³, D. Segev², D. Axelrod¹, S. Bae², V. Dharnidharka⁴, Y. Caliskan¹, S. Chang⁴, G. Hess⁵, J. Snyder⁶, M. Schnitzler¹
¹Saint Louis Univ, Saint Louis, MO, ²Johns Hopkins, Baltimore, MD, ³Univ of California, Los Angeles, Los Angeles, CA, ⁴Washington Univ, Saint Louis, MO, ⁵Drexel Univ, Philadelphia, PA, ⁶SRTR, Minneapolis, MN
*Purpose: Posttransplant diabetes mellitus (PTDM) is a common complication after kidney transplantation (KTx), which may be exacerbated by immunosuppressive therapy (ISx). Older adults tend to…
2021 American Transplant Congress
Belatacept Conversion in Elderly Renal Transplant Recipients
M. Durst¹, D. Felix¹, M. Jorgenson¹, J. Descourouez¹, B. C. Astor², D. Mandelbrot²
¹UW Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
*Purpose: Describe the impact of conversion from a calcineurin inhibitor (CNI) based immunosuppressive regimen to belatacept in elderly renal transplant recipients.*Methods: Adult renal transplant patients…
2021 American Transplant Congress
Frailty Component Trajectories Among Kidney Transplant Recipients
N. Chu, X. Chen, D. Segev, M. McAdams-DeMarco
Johns Hopkins, Baltimore, MD
*Purpose: Frailty is associated with decreased access to kidney transplantation (KT) and poor post-KT outcomes. Little is known about how an acute stressor, like KT,…
2021 American Transplant Congress
The Impact of Donor Age and Donor-Recipient Age Difference on Living Donor Kidney Transplantation
T. Hiramitsu¹, T. Tomosugi², K. Futamura², M. Okada², N. Goto², T. Ichimori², S. Narumi², Y. Watarai²
¹Nagoya Daini Red Cross Hospital, Myokencho Showaku, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan
*Purpose: The impact of donor age and donor-recipient age difference on living donor kidney transplantation have not been investigated simultaneously.*Methods: A total 805 adult living…
2021 American Transplant Congress
Initial Experience with Single-port Robotic-assisted Kidney Transplantation
M. Eltemamy, A. Aminsharifi, Y. Lin, Z. Schwen, M. Abou Zeinab, V. Krishnamurthi, D. Goldfarb, A. Wee, J. Kaouk
Cleveland Clinic, Cleveland, OH
*Purpose: Early experiences with multi-port robotic kidney transplantation have demonstrated a potential reduction in complications and improved convalescence while maintaining equivalent functional outcomes relative to…
2021 American Transplant Congress
Development and Validation of a Nomogram for Remnant Kidney Function After Living-donor Donation
M. Dou, P. Tian, B. Zheng, G. Deng, Y. Shi, C. Ding
The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
*Purpose: This study was to develop and validate a nomogram to predict remnant kidney function after living-donor kidney donation.*Methods: We conducted a retrospective cohort study…
2021 American Transplant Congress
Maternal Perinatal Condition and Neonatal Growth and Development After Renal Transplantation
X. Feng, T. Song, Q. Zhong, J. Zeng, X. Wang, Y. Fan, Z. Huang, T. Lin
Department of Urology, Institute of Urology, Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, China
*Purpose: Although pregnancy and delivery after kidney transplantation have been reported in many studies , it is still little known about growth and development of…
2021 American Transplant Congress
Clinical Validation and Performance of Donor-Derived Cell-Free DNA in Allograft Rejection
S. Anand¹, A. Pai², J. S. Bromberg³, G. Gupta⁴, I. Moinuddin⁴, T. Alhamad⁵, V. Bowers⁶, S. Ghosh⁷, W. Tian⁷, L. Bu⁸, E. Stites⁹
¹Intermountain Medical Center, Murray, UT, ²University of Texas McGovern Medical School, Houston, TX, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Washington University in St. Louis, St. Louis, MO, ⁶Tampa General Hospital, Tampa, FL, ⁷CareDx, Brisbane, CA, ⁸University of Minnesota, Minneapolis, MN, ⁹University of Colorado, Aurora, CO
*Purpose: Extensive literature regarding the utility of donor-derived cell-free DNA (dd-cfDNA) shares various thresholds for active rejection (AR) based on differing data sets for both…
2021 American Transplant Congress
Detection of Rejection in Kidney Transplant Patients Using an Algorithm That Combines Donor Fraction and Absolute Donor-derived Cell-free DNA
S. Bunnapradist¹, E. Ahmed², M. Maninder², Z. P. Demko², P. R. Billings², H. Tabriziani², P. Gauthier³
¹David Geffen Sch of Med @ UCLA, Los Angeles, CA, ²Natera, Inc., San Carlos, CA, ³Natera, Inc., Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the plasma of renal allograft patients is a clinically validated biomarker for allograft injury and rejection. Several dd-cfDNA assays…